Fig 1.
Chemical structure of FDG-mNP and disruption of cancer cell.
Fig 2.
Growth profiles of mice injected at 3 weeks of age with 8mk/kg ICG-conjugated FDG-mNPs (A). Representative fluorescent images of kidney (B, D) and brain (C, E) tissue sections from 3 and 6 month old mice injected with ICG-conjugated FDG-mNPs. Tissue intensity (arbitrary units) staining for ICG-conjugated FDG-mNPs normalised to nuclear Hoechst signal in 3 and 6 month old mice (F). n = 1 mouse per treatment group. Images in B-E are at 10x magnification. FDG: fluorodeoxyglucose; ICG: indocyanine; mNP: magnetic nanoparticle.
Fig 3.
MRI scans of tumorous hind limb of mice before and after intratumoural (A) and intravenous (B) application of FDG-mNPs. A: The MRI scans of an animal before and after intratumoural injection of FDG-mNPs. T2-weighted gradient echo imaging and multi-echo fast spin echo imaging on a pre-, hour 1st and 24th of injection. B: The MRI scans of an animal before and after intravenous injection of FDG-mNPs. T2-weighted gradient echo imaging and multi-echo fast spin echo imaging on a pre-, hour 1st and 24th of injection. FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle; MRI: magnetic resonance imaging.
Fig 4.
Representative Haemotoxylin and Eosin stained sections from mice injected with ICG-conjugated FDG-mNPs at a concentration of 8mk/kg.
Sections show representative images of brain (A), heart (B), kidney (C), liver (D), lung (E), spleen (F) and muscle (G) in a 3 month old mouse. Sections also show representative images of brain (H), heart (I), kidney (J), liver (K), lung (L), spleen (M) and muscle (N) in a 6 month old mouse. All images are at 10x magnification. FDG: fluorodeoxyglucose; ICG: indocyanine; mNP: magnetic nanoparticle.
Fig 5.
Illustration of signal intensity relative to muscle in tumour and in normal organs (liver, spleen, kidney and node) after intravenous injection of FDG-mNPs.
FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle.
Fig 6.
Illustration of signal intensity relative to muscle in tumour and in normal organs (liver, spleen, kidney and node) after intratumoural of FDG-mNPs.
FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle.
Fig 7.
Histological analyses of tumour, muscle, liver and spleen after intratumoural and intravenous injections of FGD-mNPs.
FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle.
Fig 8.
Histological analyses of tumour, muscle, liver and spleen after intravenous injections of FGD-mNPs after 1 hr and 7 days.
FDG: fluorodeoxyglucose; mNP: magnetic nanoparticle.